APPLIED GENETIC TECHNOLOGIES (AGTC) Stock Price, Quote, News and Overview
NASDAQ:AGTC - Nasdaq - US03820J1007 - Common Stock - Currency: USD
AGTC Quote, Performance and Key Statistics
0.3936
+0 (+1.23%)
The current stock price of AGTC is 0.3936 USD. In the past month the price decreased by -4.23%. In the past year, price decreased by -79.71%.
AGTC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AGTC
Company Profile
Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The company is headquartered in Alachua, Florida and currently employs 102 full-time employees. The company went IPO on 2014-03-27. The firm uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). The company has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.
Company Info
APPLIED GENETIC TECHNOLOGIES
Suite D, 11801 Research Drive
Alachua FLORIDA 32615 US
CEO: Susan B. Washer
Employees: 102
Company Website: https://www.agtc.com/
Phone: 13864622204.0
APPLIED GENETIC TECHNOLOGIES / AGTC FAQ
What is the stock price of APPLIED GENETIC TECHNOLOGIES today?
The current stock price of AGTC is 0.3936 USD. The price increased by 1.23% in the last trading session.
What is the ticker symbol for APPLIED GENETIC TECHNOLOGIES stock?
The exchange symbol of APPLIED GENETIC TECHNOLOGIES is AGTC and it is listed on the Nasdaq exchange.
On which exchange is AGTC stock listed?
AGTC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for APPLIED GENETIC TECHNOLOGIES stock?
10 analysts have analysed AGTC and the average price target is 0.37 USD. This implies a price decrease of -6.71% is expected in the next year compared to the current price of 0.3936. Check the APPLIED GENETIC TECHNOLOGIES stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is APPLIED GENETIC TECHNOLOGIES worth?
APPLIED GENETIC TECHNOLOGIES (AGTC) has a market capitalization of 26.62M USD. This makes AGTC a Nano Cap stock.
How many employees does APPLIED GENETIC TECHNOLOGIES have?
APPLIED GENETIC TECHNOLOGIES (AGTC) currently has 102 employees.
What are the support and resistance levels for APPLIED GENETIC TECHNOLOGIES (AGTC) stock?
APPLIED GENETIC TECHNOLOGIES (AGTC) has a support level at 0.37 and a resistance level at 0.4. Check the full technical report for a detailed analysis of AGTC support and resistance levels.
Should I buy APPLIED GENETIC TECHNOLOGIES (AGTC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AGTC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AGTC, evaluating the profitability, health, valuation and growth aspects
- APPLIED GENETIC TECHNOLOGIES (AGTC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APPLIED GENETIC TECHNOLOGIES (AGTC) Sales and EPS estimates to see what analysts future expectations are.
- APPLIED GENETIC TECHNOLOGIES (AGTC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APPLIED GENETIC TECHNOLOGIES (AGTC) Insider and Institutional Ownership to learn about the owners and their transactions.
- APPLIED GENETIC TECHNOLOGIES (AGTC) Stock Chart to make your own analysis
- APPLIED GENETIC TECHNOLOGIES (AGTC) Latest news and press-releases to stay up to date.
Does APPLIED GENETIC TECHNOLOGIES (AGTC) stock pay dividends?
AGTC does not pay a dividend.
When does APPLIED GENETIC TECHNOLOGIES (AGTC) report earnings?
APPLIED GENETIC TECHNOLOGIES (AGTC) will report earnings on 2023-02-13.
What is the Price/Earnings (PE) ratio of APPLIED GENETIC TECHNOLOGIES (AGTC)?
APPLIED GENETIC TECHNOLOGIES (AGTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
AGTC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AGTC. When comparing the yearly performance of all stocks, AGTC is a bad performer in the overall market: 83.06% of all stocks are doing better.
AGTC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AGTC. Both the profitability and financial health of AGTC have multiple concerns.
AGTC Financial Highlights
Over the last trailing twelve months AGTC reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 15.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.5% | ||
| ROE | N/A | ||
| Debt/Equity | 0.39 |
AGTC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 50% to AGTC. The Buy consensus is the average rating of analysts ratings from 10 analysts.